Loteprednol etabonate + Moxifloxacin in pharma franchise in Sikkim

Loteprednol etabonate + Moxifloxacin in PCD pharma franchise in Chandigarh

Loteprednol etabonate + Moxifloxacin in PCD pharma franchise in Chandigarh

Loteprednol etabonate + Moxifloxacin pcd pharma supplier in Hubli-Dharwad

Loteprednol etabonate + Moxifloxacin in phama franchise company in India
Loteprednol etabonate + Moxifloxacin in phama distributor in Bhubaneswar

Home/Products /loteprednol-etabonate-0-5-w-v-moxifloxacin-0-point-5-w-v-eye-drop

Moxolunic LP Eye Drops

Composition : Loteprednol etabonate (0.5% w/v) + Moxifloxacin (0.5% w/v)

Dosage Form : Eye drop

Packaging Type : vial

Packaging : 5 ml

Price : ₹214/-

Moxolunic LP Eye Drop is a combination ophthalmic solution containing Loteprednol etabonate (0.5% w/v), a corticosteroid, and Moxifloxacin (0.5% w/v), a broad-spectrum antibiotic. This synergistic formulation is designed to effectively manage inflammatory and bacterial eye conditions, offering relief from discomfort while addressing underlying infections.

Loteprednol etabonate reduces inflammation, redness, swelling, and itching in the eyes by inhibiting the body's inflammatory response. Its targeted action minimizes the risk of systemic side effects commonly associated with corticosteroids. Moxifloxacin, a fluoroquinolone antibiotic, eliminates bacteria by interfering with their DNA synthesis, ensuring quick and effective treatment of bacterial infections.

Moxolunic LP Eye Drop is indicated for post-operative inflammation, bacterial conjunctivitis, and other conditions requiring combined anti-inflammatory and antimicrobial therapy. It provides dual benefits: controlling infection and reducing associated inflammation, ensuring faster recovery and enhanced comfort.

The formulation is well-tolerated and delivers precise dosing, making it suitable for adult and pediatric use under medical supervision. It offers a convenient and effective solution for maintaining eye health and preventing complications arising from bacterial infections or inflammation.

Read More

About the Product

Moxolunic LP Eye Drop is a combination ophthalmic solution containing Loteprednol etabonate (0.5% w/v), a corticosteroid, and Moxifloxacin (0.5% w/v), a broad-spectrum antibiotic. This synergistic formulation is designed to effectively manage inflammatory and bacterial eye conditions, offering relief from discomfort while addressing underlying infections.

Loteprednol etabonate reduces inflammation, redness, swelling, and itching in the eyes by inhibiting the body's inflammatory response. Its targeted action minimizes the risk of systemic side effects commonly associated with corticosteroids. Moxifloxacin, a fluoroquinolone antibiotic, eliminates bacteria by interfering with their DNA synthesis, ensuring quick and effective treatment of bacterial infections.

Moxolunic LP Eye Drop is indicated for post-operative inflammation, bacterial conjunctivitis, and other conditions requiring combined anti-inflammatory and antimicrobial therapy. It provides dual benefits: controlling infection and reducing associated inflammation, ensuring faster recovery and enhanced comfort.

The formulation is well-tolerated and delivers precise dosing, making it suitable for adult and pediatric use under medical supervision. It offers a convenient and effective solution for maintaining eye health and preventing complications arising from bacterial infections or inflammation.

Mild irritation, redness, or blurred vision may occur temporarily.

For the treatment of bacterial conjunctivitis, post-surgical inflammation, and other inflammatory eye conditions with a risk of bacterial infections.

Do not use if allergic to any ingredients. Avoid touching the dropper tip to prevent contamination.

Store below 25°C. Protect from light and keep the bottle tightly closed.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation